A multi-center, open-label, randomized clinical trial evaluating the preventive effect of perampanel on craniotomy-induced epileptogenesis in seizure-naive patients with supratentorial brain tumors: study protocol for a GRAMPAS trial
Open Access
- 24 December 2024
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 25 (1) , 849
Abstract
BackgroundEarly seizures after craniotomy are significant perioperative complications that can adversely impact patient outcomes. Despite current guidelines advising against the routine use of antiseizure drugs for seizure after craniotomy prevention due to limited efficacy data, many clinicians continue prescribing them. This discrepancy highlights the need for robust evidence to guide clinical practice. This multi-center, randomized clinical trial was designed to investigate the efficacy of perampanel in preventing early seizures after craniotomy.MethodThis multi-center, open-label, randomized clinical trial will be conducted across five hospitals in Nagoya, Japan, from February 2024 to December 2026. A total of 142 seizure-naive patients with supratentorial brain tumors will be recruited and randomized (1:1) into the treatment and control groups. The treatment group will receive 2 mg of perampanel starting 2 days preoperatively and continuing for 28 days postoperatively, while the control group will receive no antiseizure drugs. The primary outcome is the incidence of seizures within 28 days after craniotomy. Secondary outcomes are length of hospital and intensive care unit stays and postoperative complications.DiscussionThis study addresses the critical need for evidence-based recommendations regarding antiseizure drug use for preventing early seizures after craniotomy. As the first multi-center, randomized trial evaluating perampanel's efficacy in this setting, the findings may significantly influence clinical guidelines and perioperative practices.Trial registrationThis trial was registered with the Japan Registry of Clinical Trials (approval number: jRCTs041230117) on December 18, 2023, a member of the Primary Registry Network of the World Health Organization's International Clinical Trials Registry Platform.Keywords
All Related Versions
This publication has 24 references indexed in Scilit:
- SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumorsNeuro-Oncology, 2021
- Postoperative seizure control in patients with tumor‐associated epilepsyEpilepsia, 2016
- The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonistEpilepsia, 2014
- Discovery of 2-(2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (Perampanel): A Novel, Noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropanoic Acid (AMPA) Receptor AntagonistJournal of Medicinal Chemistry, 2012
- Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatmentsNeuro-Oncology, 2012
- Epidemiological study of primary intracranial tumors: a regional survey in Kumamoto prefecture in southern Japan—20-year studyInternational Journal of Clinical Oncology, 2011
- Epilepsy in brain tumor patientsCurrent Opinion in Neurology, 2010
- Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experienceJournal of Neuro-Oncology, 2009
- Results of a Survey of Neurosurgical Practice Patterns Regarding the Prophylactic use of Anti-Epilepsy Drugs in Patients with Brain TumorsJournal of Neuro-Oncology, 2005
- Epilepsy in low‐grade gliomas: The impact on cognitive function and quality of lifeAnnals of Neurology, 2003